L&c Bio KRX:290650KOSDAQ
엘앤씨바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h8
Articles, 7 days9
DART filings, 7 days2
Articles tracked9since Sep 11
In Q2 2026, L&c Bio reported revenue of ₩38.8bn, up 88.4% year on year, and operating profit of ₩8.6bn. L&c Bio (엘앤씨바이오) appeared in 9 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Sep 14 with 7 articles. The most common catalyst was clinical & approvals (1).
L&c Bio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩38.8bn | +88.4% | ₩8.6bn | −₩28.1bn |
| Q1 2026 | ₩30.3bn | +70.6% | ₩6.0bn | ₩2.7bn |
| Q4 2025 derived | ₩24.7bn | +29.2% | ₩2.0bn | −₩72.0bn |
| Q3 2025 | ₩22.6bn | +21.6% | ₩2.9bn | −₩51.3bn |
| Q2 2025 | ₩20.6bn | +15.4% | −₩245m | −₩14.3bn |
| Q1 2025 | ₩17.8bn | +7.4% | −₩433m | −₩642m |
| Q4 2024 derived | ₩19.1bn | +35.5% | −₩622m | ₩144bn |
| Q3 2024 | ₩18.5bn | -9.8% | ₩175m | −₩5.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
L&c Bio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
Latest L&c Bio news Korean headlines
-
엘앤씨바이오, ‘리투오’ 남미 페루 정식 허가
5 more on this story · 4 outlets
- 엘앤씨바이오 ‘리투오’, 페루 정식 허가…남미 확장·美 진출 가시화더바이오 · Sep 14 15:23
- 엘앤씨바이오 ‘리투오’, 페루 정식 허가…남미 시장 진출이데일리증권 · Sep 14 15:25
- 엘앤씨바이오 ‘리투오’, 페루 정식 허가…남미 시장 진출이데일리 · Sep 14 15:25
- 엘앤씨바이오 ‘리투오’, 페루 정식 허가…남미 시장 진출이데일리 · Sep 14 15:25
- 엘앤씨바이오 '리투오', 페루 허가…남미 시장 진출히트뉴스 · Sep 14 15:28